Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Classificação em ações #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Preço da ação
$2.65
Última sincronização: 2024-04-03
Valor de mercado
$115.71M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Kinnate Biopharma Inc. (KNTE)

Categoria

Rácio P/S de Kinnate Biopharma Inc. (KNTE)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Kinnate Biopharma Inc., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Kinnate Biopharma Inc. de 2026 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH